Doripenem-d4 is intended for use as an internal standard for the quantification of doripenem by GC- or LC-MS. Doripenem is a broad-spectrum antibiotic in the β-lactam subclass known as carbapenems.1,2 It is active against Gram-negative and Gram-positive bacteria, including S. aureus, S. pneumoniae, E. coli, and K. pneumoniae (MICs = 0.03-0.06, 0.016-0.06, <0.015-0.3, and 0.03-0.06 µg/ml, respectively).1,2,3,4 Doripenem reduces the number of viable bacteria in mouse lung in a model of chronic P. aeruginosa respiratory tract infection when administered at a dose of 100 mg/kg per day.5 It inhibits bacterial cell wall synthesis by forming stable acyl enzymes with penicillin-binding proteins, thereby inactivating them.2 Formulations containing doripenem have been used in the treatment of bacterial infections.
1.Mandell, L.Doripenem: A new carbapenem in the treatment of nosocomial infectionClin. Infect. Dis.49(Suppl 1)S1-S3(2009) 2.Paterson, D.L., and DePestel, D.D.DoripenemClin. Infect. Dis.49(2)291-298(2009) 3.Papp-Wallace, K.M., Endimiani, A., Taracila, M.A., et al.Carbapenems: Past, present, and futureAntimicrob. Agents Chemother.55(11)4943-4960(2011) 4.El Solh, A.A., and Alhajhusain, A.Update on the treatment of Pseudomonas aeruginosa pneumoniaJ. Antimicrob. Chemother.64(2)229-238(2009) 5.Araki, N., Yanagihara, K., Morinaga, Y., et al.In vivo efficacy of doripenem (DRPM) against Pseudomonas aeruginosa in murine chronic respiratory tract infection modelJ. Infect. Chemother.17(3)318-321(2011)